1Trachoma Control Program, The Carter Center, Atlanta, Georgia.
2Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia.
Am J Trop Med Hyg. 2021 Jan;104(1):207-215. doi: 10.4269/ajtmh.20-0777.
The Trachoma Control Program in Amhara region, Ethiopia, scaled up the surgery, antibiotics, facial cleanliness, and environmental improvement (SAFE) strategy in all districts starting in 2007. Despite these efforts, many districts still require additional years of SAFE. In 2017, four districts were selected for the assessment of antibody responses against antigens and infection to better understand transmission. Districts with differing endemicity were chosen, whereby one had a previous trachomatous inflammation-follicular (TF) prevalence of ≥ 30% (Andabet), one had a prevalence between 10% and 29.9% (Dera), one had a prevalence between 5% and 10% (Woreta town), and one had a previous TF prevalence of < 5% (Alefa) and had not received antibiotic intervention for 2 years. Survey teams assessed trachoma clinical signs and took conjunctival swabs and dried blood spots (DBS) to measure infection and antibody responses. Trachomatous inflammation-follicular prevalence among children aged 1-9 years was 37.0% (95% CI: 31.1-43.3) for Andabet, 14.7% (95% CI: 10.0-20.5) for Dera, and < 5% for Woreta town and Alefa. infection was only detected in Andabet (11.3%). Within these districts, 2,195 children provided DBS. The prevalence of antibody responses to the antigen Pgp3 was 36.9% (95% CI: 29.0-45.6%) for Andabet, 11.3% (95% CI: 5.9-20.6%) for Dera, and < 5% for Woreta town and Alefa. Seroconversion rate for Pgp3 in Andabet was 0.094 (95% CI: 0.069-0.128) events per year. In Andabet district, where SAFE implementation has occurred for 11 years, the antibody data support the finding of persistently high levels of trachoma transmission.
埃塞俄比亚阿姆哈拉地区的沙眼控制项目于 2007 年开始在所有地区扩大手术、抗生素、面部清洁和环境改善(SAFE)策略。尽管做出了这些努力,但许多地区仍需要额外数年的 SAFE 措施。2017 年,选择了四个地区评估针对 抗原和 感染的抗体反应,以更好地了解传播情况。选择了具有不同流行程度的地区,其中一个地区先前的沙眼滤泡性炎症(TF)患病率≥30%(安巴德),一个地区的患病率在 10%至 29.9%之间(德拉),一个地区的患病率在 5%至 10%之间(沃雷塔镇),一个地区先前的 TF 患病率<5%(阿莱法)且两年内未接受抗生素干预。调查小组评估了沙眼临床体征,并采集了结膜拭子和干血斑(DBS)以测量感染和抗体反应。1-9 岁儿童的沙眼滤泡性炎症患病率为 37.0%(95%CI:31.1-43.3),安巴德为 14.7%(95%CI:10.0-20.5),德拉为<5%,沃雷塔镇和阿莱法为<5%。仅在安巴德检测到 感染(11.3%)。在这些地区,有 2195 名儿童提供了 DBS。对 Pgp3 抗原的抗体反应的患病率为 36.9%(95%CI:29.0-45.6%),安巴德为 11.3%(95%CI:5.9-20.6%),德拉为<5%,沃雷塔镇和阿莱法为<5%。安巴德 Pgp3 的血清转化率为每年 0.094(95%CI:0.069-0.128)事件。在 SAFE 实施了 11 年的安巴德地区,抗体数据支持持续高水平的沙眼传播的发现。